Methadone
Skeletal formula of methadone's enantiomers. (S) corresponds to the D-enantiomer, and (R) corresponds to the L-enantiomer. | |||
| Clinical data | |||
|---|---|---|---|
| Trade names | Dolophine, Methadose, Methatab,[1] others | ||
| AHFS/Drugs.com | Monograph | ||
| MedlinePlus | a682134 | ||
| License data | |||
| Pregnancy category |
| ||
| Addiction liability | High[2] | ||
| Routes of administration | By mouth, intravenous, insufflation, sublingual, rectal | ||
| Drug class | Opioid | ||
| ATC code | |||
| Legal status | |||
| Legal status |
| ||
| Pharmacokinetic data | |||
| Bioavailability | Rectal: 76% IV/IM: 100% [3] | ||
| Protein binding | 85–90%[3] | ||
| Metabolism | Liver (CYP3A4, CYP2B6 and CYP2D6-mediated)[3][5] | ||
| Onset of action | Rapid[4] | ||
| Elimination half-life | 15–55 hours[5] | ||
| Duration of action | Single dose: 4–8 h Prolonged use: • Withdrawal prevention: 1–2 days[4] • Pain relief: 8–12 hours[4][6] | ||
| Excretion | Urine, faeces[5] | ||
| Identifiers | |||
IUPAC name
| |||
| CAS Number | |||
| PubChem CID | |||
| IUPHAR/BPS | |||
| DrugBank | |||
| ChemSpider | |||
| UNII | |||
| KEGG | |||
| ChEBI | |||
| ChEMBL | |||
| CompTox Dashboard (EPA) | |||
| ECHA InfoCard | 100.000.907 | ||
| Chemical and physical data | |||
| Formula | C21H27NO | ||
| Molar mass | 309.453 g·mol−1 | ||
| 3D model (JSmol) | |||
SMILES
| |||
InChI
| |||
| (what is this?) (verify) | |||
Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid used medically to treat chronic pain and opioid use disorder.[4] Prescribed for daily use, the medicine relieves cravings and opioid withdrawal symptoms.[7] Withdrawal management using methadone can be accomplished in less than a month,[8] or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life.[4] While a single dose has a rapid effect, maximum effect can take up to five days of use.[4][9] After long-term use, in people with normal liver function, effects last 8 to 36 hours.[4][6] Methadone is usually taken by mouth and rarely by injection into a muscle or vein.[4]
Side effects are similar to those of other opioids.[4] These frequently include dizziness, sleepiness, nausea, vomiting, and sweating.[4][10] Serious risks include opioid abuse and respiratory depression.[4] Abnormal heart rhythms may also occur due to a prolonged QT interval.[4] The number of deaths in the United States involving methadone poisoning declined from 4,418 in 2011[11] to 3,300 in 2015.[12] Risks are greater with higher doses.[13] Methadone is made by chemical synthesis and acts on opioid receptors.[4]
Methadone was developed in Germany in the late 1930s by Gustav Ehrhart and Max Bockmühl.[14][15] It was approved for use as an analgesic in the United States in 1947, and has been used in the treatment of addiction since the 1960s.[4][16] It is on the World Health Organization's List of Essential Medicines.[17]
- ^ "Methatabs - Methadone Hydrochloride BP" (PDF). Medsafe. New Zealand Consumer Medicine Information. 23 October 2023.
- ^ Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN 9781455701506.
- ^ a b c d e Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O (August 2008). "Clinical pharmacology of methadone for pain". Acta Anaesthesiologica Scandinavica. 52 (7): 879–889. doi:10.1111/j.1399-6576.2008.01597.x. PMID 18331375. S2CID 25626479.
- ^ a b c d e f g h i j k l m n "Methadone Hydrochloride". The American Society of Health-System Pharmacists. Archived from the original on 23 December 2015. Retrieved 22 December 2015.
- ^ a b c Brown R, Kraus C, Fleming M, Reddy S (November 2004). "Methadone: applied pharmacology and use as adjunctive treatment in chronic pain" (PDF). Postgraduate Medical Journal. 80 (949): 654–659. doi:10.1136/pgmj.2004.022988. PMC 1743125. PMID 15537850. Archived (PDF) from the original on 2 May 2014.
- ^ a b Toombs JD, Kral LA (April 2005). "Methadone treatment for pain states". American Family Physician. 71 (7): 1353–1358. PMID 15832538. Archived from the original on 5 September 2017.
- ^ Cite error: The named reference
JosephStancliffLangrodwas invoked but never defined (see the help page). - ^ World Health Organization (2009). Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings. Geneva: World Health Organization.
- ^ Grissinger M (August 2011). "Keeping patients safe from methadone overdoses". P & T. 36 (8): 462–466. PMC 3171821. PMID 21935293.
- ^ "Methadone". The Substance Abuse and Mental Health Services Administration. 16 June 2015. Retrieved 14 October 2020.
- ^ "Data table for Figure 1. Age-adjusted drug-poisoning and opioid-analgesic poisoning death rates: United States, 1999–2011" (PDF). CDC. Archived (PDF) from the original on 23 November 2015. Retrieved 22 December 2015.
- ^ Rudd RA, Seth P, David F, Scholl L (December 2016). "Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015". MMWR. Morbidity and Mortality Weekly Report. 65 (50–51): 1445–1452. doi:10.15585/mmwr.mm655051e1. PMID 28033313.
- ^ Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. (February 2015). "The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop". Annals of Internal Medicine. 162 (4): 276–286. doi:10.7326/M14-2559. PMID 25581257. S2CID 207538295.
- ^ Methadone Matters: Evolving Community Methadone Treatment of Opiate Addiction. CRC Press. 2003. p. 13. ISBN 9780203633090. Archived from the original on 23 December 2015.
- ^ Kleiman MA, Hawdon JE (2011). "Diphenypropylamine Derivatives". Encyclopedia of Drug Policy. SAGE Publications. ISBN 9781506338248. Archived from the original on 23 December 2015.
- ^ Kuehn, B. M. (2005). Methadone Treatment Marks 40 Years. JAMA: The Journal of the American Medical Association, 294(8), 887–889. doi:10.1001/jama.294.8.887
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.